Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation [Yahoo! Finance]
iTeos Therapeutics, Inc. (ITOS)
Company Research
Source: Yahoo! Finance
Newly appointed CEO, Dr Xavier Leroy, will lead GIO Therapeutics in advancing groundbreaking research on GPCR-targeted drugs for oncology and inflammatory diseases Dr Tilly Bingham, appointed CSO/COO, is also selected from the Cumulus team to spearhead the drug development initiatives at GIO Therapeutics Edinburgh, Scotland, 1 February 2024 – Cumulus Oncology (a biotech creation company) today proudly unveils the inauguration of GIO Therapeutics AG, based in Basel, Switzerland. This newly established biotech company specialises in the development of pharmaceuticals targeting G protein-coupled receptors (GPCR). Heading GIO Therapeutics is Dr Xavier Leroy who has been appointed as Chief Executive Officer. He is a leading expert in GPCRs and immunology with a successful track record of advancing first-in-class drugs into clinical development. Dr Leroy has more than 25 years of experience in innovative drug discovery and clinical development, with past R&D leadership positions at Dom
Show less
Read more
Impact Snapshot
Event Time:
ITOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITOS alerts
High impacting iTeos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ITOS
News
- iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]Yahoo! Finance
- iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024GlobeNewswire
- iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock, down previously from $25.00.MarketBeat
- iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of DirectorsGlobeNewswire
ITOS
Earnings
- 11/7/23 - Beat
ITOS
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- ITOS's page on the SEC website